Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 14/20 | 0.54 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1414884 | 0.90 | CYP17A1 (0.56) | CYP17A1CYP2C8CYP3A4 | |
| SCHEMBL1414897 | 0.90 | CYP17A1 (0.55) | CYP17A1CYP2C8CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1414930 | 0.86 | CYP17A1 (0.70) | CYP17A1CYP2C8CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1414978 | 0.85 | CYP17A1 (0.58) | CYP17A1CYP2C8CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1415031 | 0.83 | CYP17A1 (0.56) | CYP17A1CYP2C8CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1414975 | 0.82 | CYP17A1 (0.55) | CYP17A1CYP2C8CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1415018 | 0.78 | CYP17A1 (0.68) | CYP17A1CYP2C8CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1414808 | 0.77 | CYP17A1 (0.55) | CYP17A1CYP2C8CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1414927 | 0.75 | CYP17A1 (0.57) | CYP17A1CYP2C8CYP3A4 | |
| SCHEMBL1414829 | 0.75 | CYP17A1 (0.58) | CYP17A1CYP2C8CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1344777-B1 | IMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE | TAKEDA PHARMACEUTICAL (JP) | 2011-03-16 | — | — | EP | disclosed |
| US-6960586-B2 | Imidazole derivatives, process for their preparation and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-01 | — | — | US | disclosed |
| US-20040024039-A1 | Imidazole derivatives, process for their preparation and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-05 | — | — | US | disclosed |
| EP-1344777-A1 | IMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE | Takeda Chemical Industries, Ltd. (JP) | 2003-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024039-A1 | Imidazole derivatives, process for their preparation and their use | CYP17A1, HSD17B7, CYP51A1 | CYP17A1 1/4885CYP2C8 137/4885CYP3A4 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.